Lepu Medical Technology Co (300003) Q4 2024 earnings summary

Executive summary

• Revenue for 2024 was ¥6.10 billion, down 23.52% year-over-year; net profit attributable to shareholders was ¥247 million, down 80.37% year-over-year.

• Operating cash flow was ¥734.6 million, down 25.82% year-over-year.

• Significant asset impairment losses of ¥251 million, mainly from goodwill and inventory write-downs, impacted net profit.

• Excluding impairment, adjusted net profit attributable to shareholders was ¥438 million, down 64.94% year-over-year.

• The company remains a leading innovator in cardiovascular medical devices, with a robust R&D pipeline and international expansion.

Financial highlights

• Gross margin for medical devices was 69.60%, up 2.91 percentage points year-over-year.

• Net assets attributable to shareholders at year-end were ¥15.20 billion, down 4.85% from the previous year.

• Weighted average ROE was 1.59%, down 6.64 percentage points year-over-year.

• Basic and diluted EPS were both ¥0.1336, down 80.23% year-over-year.

• R&D investment was ¥1.17 billion, accounting for 19.09% of revenue.

Outlook and guidance

• 2025 revenue is expected to grow steadily, with a focus on cost control and margin improvement.

• Key growth drivers include commercialization of innovative cardiovascular products, expansion in consumer healthcare (ophthalmology and dermatology), and international market penetration.

• The company will continue to shift resources from generic drugs to innovative drugs and high-value medical devices.